FAST NEWS: Joinn Lab profit plunges, sending shares to 52-week low
The latest: Joinn Laboratories (China) Co. Ltd. (6127.HK; 603127.SH), China’s leading non-clinical contract research organization (CRO), announced on Tuesday it expects to report a net profit of 311 million ($43.8…
FAST NEWS: WuXi Biologics boosts new projects target
The latest: Contract drug services provider WuXi Biologics (Cayman) Inc. (2269.HK) announced on Wednesday it has raised its guidance for new projects in 2024 from 80 to 110, despite a…
Joinn profits slide as lab monkey build-up backfires
The leading provider of pre-clinical drug research has predicted its first-half profits will plummet between 70% and 80% due to the falling value of its lab animals Key Takeaways: Joinn…
Cash-strapped Viva Biotech sells stake and plans spinoff
The biotech has gained a capital injection from Temasek and a major Chinese investor, but the deal has not boosted investor confidence Key Takeaways: As well as tapping strategic investors,…
HBM rises from the ashes as a research partner for drug giants
The cash-strapped company disposed of a factory and an advanced drug pipeline to stay in business, and is now re-positioning itself as a supplier of biomedical services Key Takeaways: HBM…
What Pandemic? Joinn Lab Posts Bumper Profit Despite Covid Disruptions
Less affected by Covid-control measures that have clobbered many Chinese businesses, the pre-clinical contract research organization’s profit more than doubled in the first three quarters of 2022 Key Takeaways: Joinn…
FAST NEWS: WuXi Biologics Announces $300 Million Share Buyback
The latest: Contract drugs services provider WuXi Biologics (Cayman) Inc. (2269.HK) announced on Monday its board of directors has approved a plan to buy back up to $300 million of the…